Technology
Health
Biotechnology

Anavex

$2.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (8.40%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Anavex and other stocks, options, ETFs, and crypto commission-free!

About AVXL

Anavex Life Sciences Corp. Common Stock, also called Anavex, is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Read More Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Employees
13
Headquarters
New York, New York
Founded
2004
Market Cap
142.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
292.49K
High Today
$2.73
Low Today
$2.46
Open Price
$2.51
Volume
287.75K
52 Week High
$4.09
52 Week Low
$1.25

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Pharmaceutical
2015 IPO

AVXL News

ReutersAug 15

Edited Transcript of AVXL earnings conference call or presentation 7-Aug-19 8:30pm GMT

6

AVXL Earnings

-$0.17
-$0.13
-$0.10
-$0.06
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
-$0.17 per share
Actual
-$0.14 per share

More AVXL News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.